Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. - Wikidata - wikimedia - TriplyDB

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

http://www.wikidata.org/entity/Q35224606

about

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Oncolytic Seneca Valley Virus: past perspectives and future directions Oncolytic virotherapy for pediatric malignancies: future prospects Trial Watch-Oncolytic viruses and cancer therapy Oncolytic viruses: From bench to bedside with a focus on safety.Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Senecavirus A.Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.Validation of a competitive ELISA and a virus neutralization test for the detection and confirmation of antibodies to Senecavirus A in swine sera.Attack of the cancer-killing viruses: clinical application of oncolytic virotherapy in children.Cryo-EM Structure of Seneca Valley Virus Procapsid.Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth

P2860

Q26863779-DD869782-CCF8-45DA-A57D-8D2139D03D06 Q27468763-BCFDFC8F-4B0A-47EA-AD19-2A6EA1D98480 Q28069358-46A32B70-38B6-4126-8A30-5D5E48D5ABAE Q28072347-6F6058D8-0CBB-4CD1-9463-7D81408F853E Q34044071-5D917B3B-B80D-472B-BAA5-F0C83C35B6BB Q37346179-E344DBB3-FD69-4D61-8135-B8980DC8A1CD Q38643300-974CB335-4D81-434C-94DF-F3E28E95013C Q38883975-512FC58D-6199-43BA-B9A7-A7102FCD3F4F Q40145604-5FBBD17F-7F4C-46C5-AF35-0ED88C50A072 Q40381028-7F444227-FDA6-4A35-B7A3-015FC8A38FFB Q42170507-0ACFC4E3-E2EB-4392-980A-4A59B637FBC7 Q47269211-DE536086-DEEF-4154-81FB-5D33089E34E1 Q59136414-903D4FB5-F86D-462E-A0A1-7B3AA61D73C0

P2860

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

http://www.wikidata.org/entity/Q35224606

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@ast

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@en

type

label

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@ast

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@en

prefLabel

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@ast

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@en

P1433

Q35224606-2F4979A8-D498-4BD3-99C2-F61524838BF6

P1476

Q35224606-2AAD83A7-D668-4E84-A63C-970F1058DC92

P2093

Q35224606-037AE16E-2F1F-4697-8DFE-114C618CB24D

Q35224606-03ECDD4D-C297-4687-A333-8BD3135FCF73

Q35224606-09F6AED8-5A26-4C76-9365-DB6538FB51D5

Q35224606-6F7806D3-364B-4DCF-9849-FC47174E92E6

Q35224606-8540B21C-A8C6-4A6D-BDD4-3A7198EC23AC

Q35224606-BC081391-73F5-4C6C-B9C9-1BEDC2FF7553

P2860

Q35224606-08C227A6-6B4A-4FFC-A98A-5C3A1DDC1A2C

Q35224606-0F9BCB34-F8E9-465F-B5DE-A5F107A89BE2

Q35224606-46F7CD59-0C2A-49D9-B281-2FFFF712717C

Q35224606-4B104982-753C-4B1B-B193-5DDE2C9B09C5

Q35224606-58F9BF85-27BA-4A8A-B335-E543762D0668

Q35224606-5ABF6A23-6F47-4A53-9944-940F19D025E7

Q35224606-601535F5-5FCA-4B9D-8901-A42B2C799733

Q35224606-60C5B1B4-55CC-42CB-A36A-1DFEE2C030F7

Q35224606-624F61B9-9140-4E69-8C79-A28FC6CDE64E

Q35224606-6E11E372-2CB4-41B6-A29C-EE5C91B4071E

P304

Q35224606-DE12004C-B7ED-45F4-B139-4D81A10D9AA3

P31

Q35224606-3D947A9F-B5C4-443B-8035-7C3A987A71CD

P356

Q35224606-FF2B1712-4F9C-4C6E-B73C-D1D072C8B38E

P433

Q35224606-A4706780-6E78-448E-B531-DA5F4085CCAB

P478

Q35224606-0F776C21-947A-44AB-B462-2731850D70BD

P50

Q35224606-1718B572-75FB-451F-B07B-BD1FF22D7D1F

Q35224606-7165CD34-5F8B-44BE-A21E-02D8C08C1811

Q35224606-BF3AD09B-22A2-41FA-B367-1BCAE9616CBA

P577

Q35224606-510C9A00-CBFA-45C9-B2DB-63EC286E260C

P698

Q35224606-39C029F4-16A5-44C2-B16F-C72373F649F4

P921

Q35224606-519967F0-F5AB-4312-826F-832B70C44FD4

P932

Q35224606-F5DA2B4D-D982-40D3-A841-431F99D3EF26

P356

P1433

Pediatric Blood & Cancer

P1476

Phase I trial of Seneca Valley ...... the Children's Oncology Group.

@en

P2093

Brenda J Weigel

http://www.w3.org/2001/XMLSchema#string

Charlotte Ahern

http://www.w3.org/2001/XMLSchema#string

M Brooke Bernhardt

http://www.w3.org/2001/XMLSchema#string

Michael J Burke

http://www.w3.org/2001/XMLSchema#string

Timothy P Cripe

http://www.w3.org/2001/XMLSchema#string

Yingbei Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Thunder and lightning: immunotherapy and oncolytic viruses collide

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data.

P304

743-750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.25269

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25307519

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4376652

http://www.w3.org/2001/XMLSchema#string